Teva, Sanofi, Duvakitug, UEG Week 2026, Inflammatory Bowel Disease, Ulcerative Colitis, Crohn’s Disease, TL1A Inhibition, Phase 2b Trial, RELIEVE UCCD, Clinical Remission,

PARSIPPANY, N.J., and PARIS — October 20, 2026 Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE...